Crescent Capital BDC Inc. (CCAP)

Let's invest like private equity pros without needing seven figures. Yes, that's right—PE-style starting for as little as $8.

BDCs have entered a challenging period. This is why the market has assigned notable discounts across the board. Some BDCs have become very deeply discounted.

I am increasingly cautious on BDCs due to rising non-accruals, weaker earnings, and looser underwriting amid intense competition for private credit deals. Elevated interest rates are suppressing BDC v...

Crescent Capital BDC offers a compelling 10.9% dividend yield and trades at a 22% discount to NAV, providing a strong margin of safety. Recent headwinds, including lower NII and some non-accruals, are...

Crescent Capital BDC trades at a significant discount to NAV and offers a high 12.5% yield, but recent performance and total returns have been weak. Rising non-accruals, declining earnings, and weaken...

I'm downgrading Crescent Capital from buy to hold due to weakening fundamentals and rising economic uncertainty. Recent earnings showed sequential declines in total and net investment income, with inc...

BOOT, CCAP and HP have been added to the Zacks Rank #5 (Strong Sell) List on May 19, 2025.

Crescent Capital BDC, Inc. (NASDAQ:CCAP ) Q1 2025 - Earnings Conference Call May 15, 2025 12:00 PM ET Company Participants Dan McMahon - Head, IR Jason Breaux - CEO Henry Chung - President Gerhard Lom...

Crescent Capital BDC (CCAP) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.63 per share a year ago.

Total Return can be misleading if not supported by NAV growth, as it may include unsustainable distributions and Return of Capital. Behavioral finance shows markets are irrational, making it crucial t...